文献速递临床试验与 GCP真实世界研究与卫生经济

选择性激光小梁成形术与滴眼液作为高眼压症和青光眼一线治疗的比较(LiGHT):一项多中心随机对照试验

Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial.
PubMed 文献 · Lancet · 2019-03-09

LiGHT试验在6家英国医院纳入718例未治疗的开角型青光眼或高眼压症患者,随机分配至初始选择性激光小梁成形术组或滴眼液组。3年时两组EQ-5D评分无显著差异(0.89 vs 0.90,差0.01,95%CI -0.01至0.03,p=0.23);激光组74.2%无需滴眼液即可维持目标眼压,且无患者需青光眼手术而滴眼液组有11例。作者认为应将选择性激光小梁成形术作为一线治疗提供。

要点

  • 3年EQ-5D评分激光组0.89 vs 滴眼液组0.90,无显著差异(p=0.23)。
  • 36个月时激光组74.2%患者无需滴眼液即可维持目标眼压。
  • 激光组眼压达标访视比例93.0% vs 滴眼液组91.3%,需青光眼手术者0例 vs 11例。

核心结论

  • 作者认为应将选择性激光小梁成形术作为开角型青光眼和高眼压症的一线治疗提供,支持临床实践改变。

研究设计与样本

  • 观察者设盲的随机对照试验,2012至2014年在6家英国医院招募未治疗且无眼部合并症的开角型青光眼或高眼压症患者。
  • 718例患者随机分配至初始选择性激光小梁成形术组(356例)或滴眼液组(362例),按意向性分析。
  • 主要结局为3年时健康相关生活质量(EQ-5D评估),试验注册号ISRCTN32038223。

主要发现

  • 36个月时652例(91%)返回主要结局问卷,平均EQ-5D评分激光组0.89(SD 0.18)vs 滴眼液组0.90(SD 0.16),无显著差异(差0.01,95%CI -0.01至0.03;p=0.23)。
  • 36个月时激光组74.2%(95%CI 69.3-78.6)患者无需滴眼液即可维持目标眼压。
  • 激光组眼压达标访视比例93.0% vs 滴眼液组91.3%;需降眼压青光眼手术者激光组0例 vs 滴眼液组11例。
  • 36个月内从眼科费用角度看,在每获得1个质量调整生命年支付意愿为20000英镑时,选择性激光小梁成形术作为首次治疗比首选滴眼液更具成本效益的概率为97%。

临床怎么用

  • 作者认为应将选择性激光小梁成形术作为开角型青光眼和高眼压症的一线治疗提供。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary open angle glaucoma and ocular hypertension are habitually treated with eye drops that lower intraocular pressure. Selective laser trabeculoplasty is a safe alternative but is rarely used as first-line treatment. We compared the two. METHODS: In this observer-masked, randomised controlled trial treatment-naive patients with open angle glaucoma or ocular hypertension and no ocular comorbidities were recruited between 2012 and 2014 at six UK hospitals. They were randomly allocated (web-based randomisation) to initial selective laser trabeculoplasty or to eye drops. An objective target intraocular pressure was set according to glaucoma severity. The primary outcome was health-related quality of life (HRQoL) at 3 years (assessed by EQ-5D). Secondary outcomes were cost and cost-effectiveness, disease-specific HRQoL, clinical effectiveness, and safety. Analysis was by intention to treat. This study is registered at controlled-trials.com (ISRCTN32038223). FINDINGS: Of 718 patients enrolled, 356 were randomised to the selective laser trabeculoplasty and 362 to the eye drops group. 652 (91%) returned the primary outcome questionnaire at 36 months. Average EQ-5D score was 0·89 (SD 0·18) in the selective laser trabeculoplasty group versus 0·90 (SD 0·16) in the eye drops group, with no significant difference (difference 0·01, 95% CI -0·01 to 0·03; p=0·23). At 36 months, 74·2% (95% CI 69·3-78·6) of patients in the selective laser trabeculoplasty group required no drops to maintain intraocular pressure at target. Eyes of patients in the selective laser trabeculoplasty group were within target intracoluar pressure at more visits (93·0%) than in the eye drops group (91·3%), with glaucoma surgery to lower intraocular pressure required in none versus 11 patients. Over 36 months, from an ophthalmology cost perspective, there was a 97% probability of selective laser trabeculoplasty as first treatment being more cost-effective than eye drops first at a willingness to pay of £20 000 per quality-adjusted life-year gained. INTERPRETATION: Selective laser trabeculoplasty should be offered as a first-line treatment for open angle glaucoma and ocular hypertension, supporting a change in clinical practice. FUNDING: National Institute for Health Research, Health and Technology Assessment Programme.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019. PMID: 30862377. doi:10.1016/S0140-6736(18)32213-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。